Health TrialsbyHealthPanel

Eye Disorders Congenital

2

Review clinical trials related to Eye Disorders Congenital. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Study to Evaluate the Long-Term Safety of Ultevursen in Participants With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

The purpose of this Phase 2 Open-label study is to evaluate the long-term safety and tolerability of Ultevursen administered via intravitreal injection (IVT) in participants with Retinitis Pigmentosa due to mutations in exon 13 of the USH2A gene. This is a multicenter study which will enroll approximately 81 participants, however, the exact number enrolled will depend on the final number completing the 24-month LUNA trial and are eligible and willing to enroll in CAPELLA.

Participants needed: 81
Trial details
Phase: Phase 2Age: 8+Biological sex: AllType: InterventionalSponsor: Laboratoires TheaUpdated: Sep 1, 2026
Eligibility criteria

Participants who have completed the LUNA study through Month 24 and, in the Inve... [+3]

Treatment Cohort only: New ocular condition in the SE (e.g., severe infection, u... [+5]

Read more
Status: Recruiting

Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)

The purpose of this double-masked, randomized, placebo-controlled, paired-eye study is to evaluate the efficacy, safety and tolerability of Sepofarsen in subjects with Leber Congenital Amaurosis (LCA) due to the c.2991+1655A\>G (p.Cys998X) mutation in the CEP290.

Participants needed: 32
Trial details
Phase: Phase 3Age: 6+Biological sex: AllType: InterventionalSponsor: Laboratoires TheaUpdated: Jun 25, 2026Locations: 17
Eligibility criteria

Confirmed clinical diagnosis of LCA10 and a molecular diagnosis of homozygosity... [+4]

Mutations in genes other than the CEP290 gene associated with other IRD diseases... [+4]

Read more